Article Details

AIM ImmunoTech doses first subject in Phase 2 study of Ampligen, Imfinzi | Markets Insider

Retrieved on: 2025-02-25 14:54:28

Tags for this article:

Click the tags to see associated articles and topics

AIM ImmunoTech doses first subject in Phase 2 study of Ampligen, Imfinzi | Markets Insider. View article details on hiswai:

Excerpt

AstraZeneca-stock · News for AstraZeneca · AIM ImmunoTech doses first ... AstraZeneca's (AZN) anti-PD-L1 immune checkpoint inhibitor Imfinzi in ...

Article found on: markets.businessinsider.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up